Study To Assess Long Term Safety Of Pazopanib

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

188 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-20

Study Completion Date

2018-03-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was a rollover study to evaluate the long term safety of pazopanib and to continue to provide pazopanib to patients who participated in a GSK sponsored pazopanib study until pazopanib is available commercially.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients

NCT00363194

Carcinoma, Renal Cell

COMPLETED PHASE1

A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

NCT05709158

Breast Cancer

UNKNOWN

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

NCT02393248

Lung Cancer Solid Tumor Gastric Cancer +8 more

TERMINATED PHASE1/PHASE2

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

NCT03011372

MPN (Myeloproliferative Neoplasms)

COMPLETED PHASE2

Study of the Safety and Leukostimulatory Activity of the Preparation "Panagen" in Patients With Breast Cancer

NCT02115984

Breast Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Renal Cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications

Group Type EXPERIMENTAL

Pazopanib

Intervention Type DRUG

Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pazopanib

Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participated or completed a GSK sponsored pazopanib study and remains eligible for continued treatment with pazopanib and lapatinib (if on combination therapy).
* Able to understand and provide written informed consent
* Women and men agree to use protocol specific birth control measures

Exclusion Criteria

* The subject has a treatment related serious adverse event that remains unresolved or unstable or had pazopanib permanently stopped in a previous study because of intolerate or because it was unsuccessful in treating your cancer
* If you are pregnant or breast feeding
* Your doctor does not think you would be a good candidate for the study
* Poorly controlled high blood pressure
* Subject is unwilling or unable to follow the procedures outlined in the protocol.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No